Please check the following:
- {{x.value}}
FREE membership
FREE membership
Join Intelligent Investor today
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
Please enter the 5 digit verification code sent to "{{user.DayPhone}}" Change number
We cannot send you a verification code via SMS to "{{user.DayPhone}}" Change number
{{ completedStep1 ? 'Authentication & Security' : content.trialHeading.replace('{0}', user.FirstName) }}
Please enter your mobile number and press send to receive a text message with a verification code.
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
Thank you
We have sent you an email with the details of your registration.
Purchase order
Sign up
Log in
Looks you are already a member. Please enter your password to proceed
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Log in
Upgrade Today
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
{{eventFunction.Name}}
{{eventFunction.EventTypeName}}
{{eventFunction.StartDate}}
{{eventFunction.EventTimings}}
{{eventFunction.VenueName}}
{{ t.Cost === 0 ? "FREE" : "$" + t.Cost.toFixed(2) }}
Quantity *
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
Congratulations!
You now have free access to InvestSMART, we look forward to helping you on your financial journey.
You now have access to Free Eureka Report Insights, We look forward to helping you on your financial journey.
You now have access to Intelligent Investor Free Insights. We look forward to helping you build a market beating stock portfolio.
Looking for more…
Intelligent Investor Membership
15-day Free Trial
- Indepth analysis of ASX listed shares
- BUY, Hold and Sell Recommendations
- Ideas Lab
- Special Reports
No thanks
Looking for more…
Eureka Report Membership
15-day Free Trial
- Alan Kohler’s Weekend Briefing
- Interviews with CEO’s & top influencers
- Money Cafe and Talking Finance
- Super Advice and Q&A with Ask Alan
No thanks
Clarity Pharmaceuticals Ltd (ASX: CU6) - Share Price and Research
Current share price for CU6 : $3.010 0.21 (7.50%)
Clarity(CU6), an ASX-listed company, is a leader in Targeted Copper Theranostics (TCT), developed with its proprietary SAR Technology platform. The Company has a diverse range of products in clinical trials which address both large indications (prostate cancer and breast cancer) as well as rare and orphan indications (neuroendocrine tumours (NETs) and neuroblastoma) of cancer
CU6 General Information +
| ASX Code | CU6 |
| Website | http://www.claritypharmaceuticals.com |
| Industry/Sector | Pharmaceuticals |
| Market Cap ($M) | 935 |
| CU6 Share Price | $3.010 |
| Day High | $3.040 |
| Day Low | $2.760 |
| Last Close | $2.800 |
| CU6 Share Price Movement | $0.21 ( 7.50% ) |
Prices as at 16:40, 1 May 2024
+Security prices are delayed by at least 20 minutes and are indicative only.
CU6 Related Research
Clarity Pharmaceuticals Ltd (CU6) Upcoming Dividends & Yields
There are no dividends for Clarity Pharmaceuticals Ltd (CU6). Please use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Clarity Pharmaceuticals Ltd (CU6) Recent ASX Announcements
| Headline | Annoucement date/time+ | Price at announcement+ | Current price+ | Price 7D Avg | Gain/Loss |
|---|---|---|---|---|---|
| Change of Director's Interest Notice - Thomas | 30 Apr 2024 4:04PM | $2.800 | $3.010 | $2.520 | risen by 7.50% |
| Quarterly Activities/Appendix 4C Cash Flow Report | 30 Apr 2024 3:37PM | $2.790 | $3.010 | $2.520 | risen by 7.89% |
| Complete response with Cu-67 SAR-bisPSMA | 30 Apr 2024 9:37AM | $2.560 | $3.010 | $2.520 | risen by 17.58% |
- + Company announcements and prices are delayed by at least 20 minutes. Prices are indicative only.
See all ASX announcements from Clarity Pharmaceuticals Ltd (CU6) or use our ASX Announcements tool to search for announcements across all ASX-listed securities.
CU6 Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2023A | -$24.60 | -$9.50 | -1.20% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2022A | -$23.75 | -$9.60 | 0.00% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2020A | C2 | N2 | 0.00% | 0.00 | 0.00 | 0.00% | 0.0% |
CU6 Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2020 A | 2022 A | 2023 A | 2020 A | 2022 A | 2023 A | 2020 A | 2022 A | 2023 A | ||
| Clarity Pharmaceuticals (CU6) | $796M | -0.0115 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Mayne Pharma Group (MYX) | $605M | 0.9287 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Neuren Pharmaceuticals (NEU) | $2,458M | 799.6667 | -0.5504 | 0.6667 | 16.0283 | 35.6481 | 21.3889 | 0.00% | 0.00% | 0.00% |
CU6 Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 10.58 | 0.00 |
| Market | 0.46 | 15.00 | 1.11 | 1.03 |
| Sector | 1.35 | 21.20 | 1.95 | 0.96 |
CU6 Directors
| Name | Position | Start Date |
|---|---|---|
| Dr Colin David Biggin | Chief Executive Officer, Managing Director | 1 Oct 2019 |
| Dr Alan John Taylor | Executive Chairman, Executive Director | 28 Nov 2013 |
| Dr Christopher Graham Roberts | Non-Executive Director | 24 Mar 2016 |
| Mr Robert Bain Thomas | Non-Executive Director | 25 Aug 2021 |
| Ms Rosanne Elizabeth Robinson | Non-Executive Director | 19 Oct 2010 |
| Dr Thomas Ramdahl | Non-Executive Director | 26 Mar 2019 |
Clarity Pharmaceuticals Ltd (CU6) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 29 Apr 2024 | THOMAS, Robert | Issued | Direct Shares | 16,667 | $2.550 | $42,500.850 |
| 29 Apr 2024 | THOMAS, Robert | Issued | Indirect Shares | 17,425 | $2.550 | $44,433.750 |
| 21 Mar 2024 | RAMDAHL, Thomas | Buy | Direct Shares | 400,000 | $0.605 | $242,000.000 |
See all changes in directors' interest & trades for Clarity Pharmaceuticals Ltd (CU6) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
CU6 Management
| Name | Position |
|---|---|
| David Green | Chief Financial Officer |
| Robert Cochrane Vickery | Chief Financial Officer,Company Secretary |
CU6 Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Clarity Pharmaceuticals Ltd (CU6). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 18,788,460 (7.18%) | TM Ventures Pty Ltd |
| 17,911,280 (6.84%) | Cabbit Pty Ltd |
| 13,266,660 (5.07%) | A.C.N. 136 437 913 Pty Ltd |
CU6 Calendar of Events
| Date | Event |
|---|---|
| 27 February 2025 | Report (Interim) |
| 27 September 2024 | Report (Annual) |
| 22 August 2024 | Report (Prelim) |
FAQs about Clarity Pharmaceuticals Ltd (CU6)
What is the current share price of Clarity Pharmaceuticals Ltd (CU6)?
Clarity Pharmaceuticals Ltd's (CU6) current share price is $3.01. This constitutes a price movement of 19.44% when compared to the share price 7 days ago and is 0% below CU6's 12-month high of $3.01 per share. Prices are delayed by at least 20 minutes.
What is the share price movement for Clarity Pharmaceuticals Ltd (CU6)?
Relative to the previous close share price of $2.80, Clarity Pharmaceuticals Ltd's (CU6) current share price of $3.01 constitutes a movement of $0.21 or 7.50%. Clarity Pharmaceuticals Ltd's (CU6) share price movement is 19.44% when compared to 7 days ago and is 0% below CU6's 52-week high of $3.01.
What is the 52-week high share price for Clarity Pharmaceuticals Ltd (CU6)?
Clarity Pharmaceuticals Ltd's (CU6) 52-week high is $3.01 which was reached on 1 May 2024. Relative to this, CU6's current share price of $3.01 constitutes a or 0% drop since that high of $3.01 per CU6 share.
What is the 52-week low share price for Clarity Pharmaceuticals Ltd (CU6)?
Clarity Pharmaceuticals Ltd's (CU6) 52-week low is $0.68 which was reached on 26 Jun 2023. Relative to this, CU6's current share price of $3.01 constitutes a $2.34 or 345.93% gain since that low of $0.68 per CU6 share.
What is the daily average trading volume for Clarity Pharmaceuticals Ltd (CU6)?
Over the last 12 months, Clarity Pharmaceuticals Ltd (CU6) has a daily average trading volume of 375,142 CU6 shares per day.
What is the dividend yield for Clarity Pharmaceuticals Ltd (CU6)?
Clarity Pharmaceuticals Ltd (CU6) has a current dividend yield of n/a this year. Last year's dividend yield was 0%. The dividend yield for CU6 is a ratio that tells you the percentage of Clarity Pharmaceuticals Ltd's (CU6) share price that it pays out in dividends each year.
When does Clarity Pharmaceuticals Ltd (CU6) release its next Annual Report?
Clarity Pharmaceuticals Ltd (CU6) will release its next Annual Report on 27 September 2024. Clarity Pharmaceuticals Ltd's (CU6) last annual report was released on 29 Feb 2024. Click here to view Clarity Pharmaceuticals Ltd's (CU6) last annual report.
In which sector is Clarity Pharmaceuticals Ltd (CU6) classified?
Clarity Pharmaceuticals Ltd (CU6) is classified as Health Care. Other companies in this sector include CSL Limited (CSL), Cochlear Limited (COH), ResMed Inc. (RMD), and Fisher & Paykel Healthcare Corporation Limited (FPH).
What is the price-to-earnings (P/E) ratio for Clarity Pharmaceuticals Ltd (CU6)?
The price-to-earnings (P/E) ratio for Clarity Pharmaceuticals Ltd (CU6) is 0. The price-to-earnings ratio, also known as P/E ratio, P/E, or PER, is the ratio of Clarity Pharmaceuticals Ltd's (CU6) share price to its earnings per CU6 share.
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
